Fosfomycin Susceptibility Among Esbl-Producing Escherichia Coli Causing Community Acquired Uncomplicated Urinary Tract Infections
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 7, Pages 1780-1785
AbstractIntroduction:Fosfomycin has recently gained popularity due to the emergence of multi-drug resistant bacteria and its wide range of spectrum with considerable activity against both Gram-positive and Gram-negative bacteria, including E. coli.
Objective:The present study aims to evaluate the susceptibility of ESBL-producing E. coli to fosfomycin among patients suffering from UTIs.
Materials And Methods: The study included all patients who presented to the hospital's various outpatient departments (OPDs) with symptoms of UTIs. ESBL-producing E. coli was detected by using cephalosporin/clavulanate combination discs. Fosfomycin susceptibility test was done by using fosfomycin 200 μg disc. Antimicrobial susceptibility testing was done for all the ESBL-producing E. coli.
Results:A total of 266 (37.2%) isolates were found to be ESBL producers out of 714 E. coli isolates. Only 8 (3%) isolates were resistant to fosfomycin.
Conclusion: Fosfomycin has proved to be highly effective in the treatment of multidrug-resistant bacteria such as ESBL producing E. coli, and its prudent use is advised to avoid the development of resistance.
- Article View: 37
- PDF Download: 108